Guggenheim Maintains Buy on UroGen Pharma, Lowers Price Target to $56

Benzinga · 4d ago
Guggenheim analyst Michael Schmidt maintains UroGen Pharma (NASDAQ:URGN) with a Buy and lowers the price target from $58 to $56.